Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors

被引:150
作者
Baumgart, Egbert
Cohen, Michael S.
Neto, Brasil Silva
Jacobs, Micah A.
Wotkowicz, Chad
Rieger-Christ, Kimberly M.
Biolo, Andreia
Zeheb, Ron
Loda, Massimo
Libertino, John A.
Summerhayes, Ian C.
机构
[1] Lahey Clin Fdn, Robert E Wise MD Res & Educ Inst, Cell & Mol Biol Lab, Burlington, MA 01805 USA
[2] Lahey Clin Fdn, Dept Urol, Burlington, MA 01805 USA
[3] Lahey Clin Fdn, Dept Pathol, Burlington, MA 01805 USA
[4] Hosp Clin Porto Alegre, Dept Internal Med & Cardiol, Porto Alegre, RS, Brazil
[5] Dana Farber Canc Ctr, Dept Pathol, Boston, MA USA
关键词
BETA-CATENIN; N-CADHERIN; GAMMA-CATENIN; CARCINOMA; PROGRESSION; CANCER; INVOLVEMENT; MECHANISMS; INVASION; MARKER;
D O I
10.1158/1078-0432.CCR-06-2330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Epithelial to mesenchymal transition (EMT) is reportedly an important transition in cancer progression in which the underlying cellular changes have been identified mainly using in vitro models. In this study, we examined the expression pattern of EMT markers in vivo and determined the occurrence and clinical significance of these events in a series of bladder carcinomas. Experimental Design: Eight hundred and twenty-five tumor samples from 572 bladder cancer patients were assembled in 10 tissue microarrays. Paraffin sections from each tissue microarray were subjected to antigen retrieval and processed by immunohistochemistry for the expression of E-cadherin, plakoglobin, beta-catenin, N-cadherin, and vimentin. Results: Pathologic expression of E-cadherin, beta-catenin, plakoglobin, and vimentin were associated with the clinicopathologic variables of grade and stage with only the cytoplasmic localization of plakoglobin found associated with lymph node status. Associations between the aforementioned markers were found significant as determined by the Spearman correlation coefficient with N-cadherin showing no associations in this analysis. In univariate survival analysis involving patients who underwent cystectomy, the reduction or loss of plakoglobin significantly influenced overall survival (P = 0.02) in which the median time to death was 2 years compared with 4 years when a normal level of plakoglobin was recorded. When the analysis was done for cancer-specific survival, low levels of both plakoglobin (P = 0.02) and P-catenin (P = 0.02) significantly influenced survival. Conclusion: The putative markers of EMT defined within a panel of bladder carcinoma cell lines were recorded in vivo, frequently associated with tumors of high grade and stage. Although multivariate analysis showed no significant influence of the EMT biomarkers on survival, alterations associated with plakoglobin were identified as significant prognostic features in these tumors.
引用
收藏
页码:1685 / 1694
页数:10
相关论文
共 41 条
  • [1] Aaltomaa S, 2004, ANTICANCER RES, V24, P2407
  • [2] Colorectal cancer progression -: Integrin αvβ6 and the epithelial-mesenchymal transition (EMT)
    Bates, RC
    [J]. CELL CYCLE, 2005, 4 (10) : 1350 - 1352
  • [3] Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease
    Bellovin, DI
    Bates, RC
    Muzikansky, A
    Rimm, DL
    Mercurio, AM
    [J]. CANCER RESEARCH, 2005, 65 (23) : 10938 - 10945
  • [4] Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment
    Brabletz, T
    Jung, A
    Reu, S
    Porzner, M
    Hlubek, F
    Kunz-Schughart, LA
    Knuechel, R
    Kirchner, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) : 10356 - 10361
  • [5] Expression of E-cadherin and α-, β-, γ-catenins in patients with bladder cancer -: Identification of γ-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors
    Clairotte, A
    Lascombe, I
    Fauconnet, S
    Mauny, F
    Félix, S
    Algros, MP
    Bittard, H
    Kantelip, B
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (01) : 119 - 126
  • [6] del Muro XG, 2000, EUR J CANCER, V36, P357
  • [7] Gee J, 1998, MOL UROL, V2, P73
  • [8] Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.0.CO
  • [9] 2-#
  • [10] Hay ED, 1995, ACTA ANAT, V154, P8